StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.21−0.29 (-8.29%)

Close on Nov 18, 2026Market cap $100.86MP/E –Yield –

LENZ Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

LENZ Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $21.48M, up 329.5% year over year. For fiscal 2025 it was $19.09M.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.09M–
FY2024Dec 31, 2024$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.49M+9.7%
Q1 FY2026Mar 31, 2026$1.90M–
Q4 FY2025Dec 31, 2025$1.59M–
Q3 FY2025Sep 30, 2025$12.50M–
Q2 FY2025Jun 30, 2025$5.00M–
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–

More LENZ Therapeutics figures

See a number that looks wrong?